Paul Gleeson is an Honorary Professor Emeritus in the Department of Biochemistry and Pharmacology, Bio21 Institute, University of Melbourne. He has contributed to the fields of cell biology (protein sorting, membrane trafficking), glycobiology and immunology over his career. In particular, his findings have demonstrated the importance of defining membrane trafficking and cellular architecture of specialized primary cells to understand cell function and the potential for the development of new therapeutic drugs. Paul obtained his PhD in 1980 from the University of Melbourne in plant glycobiology and did post-doctoral research in the biosynthesis and function of glycoproteins at the Hospital for Sick Children, Toronto (with Harry Schacter), National Institute for Medical research, Mill Hill London (with Colin Hughes) and Department of Biochemistry, La Trobe University, Melbourne. He established an independent laboratory at Monash University in 1986 where he defined the targeting signals of Golgi glycosyltransferases, identified golgins (membrane tethers/scaffolds) of the trans-Golgi network and along with his colleagues developed a highly-defined mouse model of organ-specific autoimmune disease, namely autoimmune gastritis. In 2001 he moved to the Department of Biochemistry and Molecular Biology at the University of Melbourne and was Head of the Department from 2006-2016. His current research over the past 10 years has focused on neuronal cell biology and membrane trafficking defects associated Alzheimer’s disease. Paul has published 208 articles/reviews, 44 articles with >100 citations, has trained 35 PhD students and 21 post-doctoral fellows, and won a number of awards including the 2024 ANZSCDB President Medal for research excellence. He has been a visiting scientist at the EMBL, Heidelberg, and the Institut Curie, Paris and was President of IGO (2007-2009) and an executive member of the FAOBMB (2018-2024).